본문 바로가기
KERD
논문KCI 등재

Serum transferrin as liver fibrosis biomarkerin patients with chronic hepatitis B

박주한|김동준|김영배|조성원|정재연|김순선|안선주|조효정
대한간학회 (The korean Association for the Study of the Liver)|2014.12|Clinical and Molecular Hepatology|제20권 제4호|pp. 347-354

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

Chronic hepatitis BLiver cirrhosisTransferrinAlpha-1 antitrypsin

초록

Background/Aims: Transferrin and alpha-1 antitrypsin are reportedly associated with liver fibrosis. We evaluated the usefulness of serum transferrin and alpha-1 antitrypsin as new liver fibrosis markers in patients with chronic hepatitis B. Methods: The study included 293 patients with chronic hepatitis B who underwent a liver biopsy between October 2005 and June 2009, and who had no history of hepatocellular carcinoma. Serum markers and liver fibrosis stages were compared. Results: Univariate analysis revealed that age (P<0.001), serum platelet count (P<0.001), and serum alkaline phosphatase level (P=0.003) differed significantly between the patients with and without liver cirrhosis. Serum transferrin levels were significantly lower in advanced fibrosis than in mild fibrosis in both univariate analysis (P=0.002) and multivariate analysis (P=0.009). In addition, the serum transferrin level was significantly lower in cirrhotic patients than in noncirrhotic patients (P=0.020). However, the serum level of alpha-1 antitrypsin was not significantly associated with liver cirrhosis in patients with chronic hepatitis B. Conclusions: Serum transferrin could be promising serum marker for predicting advanced liver fibrosis in patients with chronic hepatitis B.

Abstract

Background/Aims: Transferrin and alpha-1 antitrypsin are reportedly associated with liver fibrosis. We evaluated the usefulness of serum transferrin and alpha-1 antitrypsin as new liver fibrosis markers in patients with chronic hepatitis B. Methods: The study included 293 patients with chronic hepatitis B who underwent a liver biopsy between October 2005 and June 2009, and who had no history of hepatocellular carcinoma. Serum markers and liver fibrosis stages were compared. Results: Univariate analysis revealed that age (P<0.001), serum platelet count (P<0.001), and serum alkaline phosphatase level (P=0.003) differed significantly between the patients with and without liver cirrhosis. Serum transferrin levels were significantly lower in advanced fibrosis than in mild fibrosis in both univariate analysis (P=0.002) and multivariate analysis (P=0.009). In addition, the serum transferrin level was significantly lower in cirrhotic patients than in noncirrhotic patients (P=0.020). However, the serum level of alpha-1 antitrypsin was not significantly associated with liver cirrhosis in patients with chronic hepatitis B. Conclusions: Serum transferrin could be promising serum marker for predicting advanced liver fibrosis in patients with chronic hepatitis B.

참고문헌 (42)

  1. Friedman SL., "Liver fibrosis -- from bench to bedside", J Hepatol, 38(Suppl 1), pp.S38~S53 (2003)
  2. Suk KT, "Revision and update on clinical practice guideline for liver cirrhosis", Korean J Hepatol, 18, pp.1~21 (2012)
  3. Bravo AA, "Liver biopsy", N Engl J Med, 344, pp.495~500 (2001)
  4. Abdi W, "Sampling variability on percutaneous liver biopsy", Arch Intern Med, 139, pp.667~669 (1979)
  5. Terjung B, "Bleeding complications after percutaneous liver biopsy. An analysis of risk factors", Digestion, 67, pp.138~145 (2003)
  6. Bedossa P, "Sampling variability of liver fibrosis in chronic hepatitis C", Hepatology, 38, pp.1449~1457 (2003)
  7. Imbert-Bismut F, "Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study", Lancet, 357, pp.1069~1075 (2001)
  8. Rossi E, "Validation of the fibrotest biochemical markers score in assessing liver fibrosis in hepatitis C patients", Clin Chem, 49, pp.450~454 (2003)
  9. Poynard T, "Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin", Hepatology, 38, pp.481~492 (2003)
  10. Le Calvez S, "The predictive value of fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C", Hepatology, 39, pp.862~863 (2004)
  11. Thabut D, "Noninvasive prediction of fibrosis in patients with chronic hepatitis C", Hepatology, 37, pp.1220~1221 (2003)
  12. Forns X, "Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model", Hepatology, 36, pp.986~992 (2002)
  13. Wai CT, "A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C", Hepatology, 38, pp.518~526 (2003)
  14. Lok AS, "Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort", Hepatology, 42, pp.282~292 (2005)
  15. Leroy V, "Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid", Am J Gastroenterol, 99, pp.271~279 (2004)
  16. Myers RP, "Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B", J Hepatol, 39, pp.222~230 (2003)
  17. Cheong JY, "Noninvasive index for predicting significant liver fibrosis: comparison of diagnostic performances in patients with chronic hepatitis B and C", Dig Dis Sci, 56, pp.555~563 (2011)
  18. Franchini M, "The effect of iron depletion on chronic hepatitis C virus infection", Hepatol Int, 2, pp.335~340 (2008)
  19. Tirnitz-Parker JE, "Iron and hepatic carcinogenesis", Crit Rev Oncog, 18, pp.391~407 (2013)
  20. Vagu C, "Serum iron markers in patients with chronic hepatitis C infection", Hepat Mon, 13, pp.e13136~ (2013)
  21. Fletcher LM, "Interrelationships of alcohol and iron in liver disease with particular reference to the iron-binding proteins, ferritin and transferrin", J Gastroenterol Hepatol, 14, pp.202~214 (1999)
  22. Xu MY, "Serum proteomic MRM identify peptide ions of transferrin as new fibrosis markers in chronic hepatitis B", Biomed Pharmacother, 67, pp.561~567 (2013)
  23. Van Molle W, "Activation of caspases in lethal experimental hepatitis and prevention by acute phase proteins", J Immunol, 163, pp.5235~5241 (1999)
  24. Tan XF, "Alpha-1 antitrypsin is a potential biomarker for hepatitis B", Virol J, 8, pp.274~ (2011)
  25. Pferdmenges DC, "Prognostic marker for liver disease due to alpha1-antitrypsin deficiency", Klin Padiatr, 225, pp.257~262 (2013)
  26. Kohnlein T, "Alpha1-antitrypsin deficiency", Internist (Berl), 51(Suppl 1), pp.S269~S276 (2010)
  27. Beloborodova EV, "The parameters of collagen proteolytic and metabolic systems in chronic liver diseases of viral and toxic etiologies", Ter Arkh, 82, pp.29~34 (2010)
  28. Metwally MA, "Clinical significance of hepatic iron deposition and serum iron values in patients with chronic hepatitis C infection", Am J Gastroenterol, 99, pp.286~291 (2004)
  29. Marchesini G, "Nonalcoholic fatty liver disease a feature of the metabolic syndrome", Diabetes, 50, pp.1844~1850 (2001)
  30. Bassett ML, "Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis", Hepatology, 6, pp.24~29 (1986)
  31. Fletcher LM., "Alcohol and iron: one glass of red or more?", J Gastroenterol Hepatol, 11, pp.1039~1041 (1996)
  32. Wang J, "Regulation of cellular iron metabolism", Biochem. J, 434, pp.365~381 (2011)
  33. Andrews NC., "Disorders of iron metabolism", N Engl J Med, 341, pp.1986~1995 (1999)
  34. de Jong G, "The biology of transferrin", Clin Chim Acta, 190, pp.1~46 (1990)
  35. Potter BJ, "Transferrin metabolism in alcoholic liver disease", Hepatology, 5, pp.714~721 (1985)
  36. Ibrahim AM, "Simple and rapid detection of liver cirrhosis in children by tracking serum IgA", transferrin ratio, 2011, pp.(1), 117~121
  37. Loréal O, "Iron, hepcidin and the metal connection", Front Pharmacol, 5, pp.128~ (2014)
  38. Hino K, "Iron metabolic disorder in chronic hepatitis C : Mechanisms and relevance to hepatocarcinogenesis", J Gastroenterol Hepatol, 28, pp.93~98 (2013)
  39. Travis J, "Human plasma proteinase inhibitors", Annu Rev Biochem, 52, pp.655~709 (1983)
  40. Dickson I, "Changes in serum proteinase inhibitor levels following bone surgery", Clin Chim Acta, 54, pp.381~385 (1974)
  41. Cho HJ, "Serum markers for predicting significant necroinflammatory activity in patients with chronic hepatitis B", Clin Biochem, 45, pp.1564~1567 (2012)
  42. Hui AY, "Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model", Am J Gastroenterol, 100, pp.616~623 (2005)

이 간행물의 다른 논문 (7건)

Is it necessary to delay antiviral therapy for 3.6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?송현주, 나수영, 송병철, 부선진, 김흥업, 최은광, 정승욱, 좌혜영, 조유경pp. 355-360Geographic difference of epidemiological features of HCV infection in Korea장은선, 강천, 김영석, 이연재, 김경아, 정숙향, 기미경, 조성범, 김인희, 정은욱pp. 361-367Predictors of spontaneous viral clearance and outcomes of acute hepatitis C김영남, 송병철, 조유경pp. 368-375Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension차승환, 김영주, 백순구, 김재현, 권상옥, 강혜원, 김현아, 김현식, 나지훈, 조윤주, 김정민, 김문영pp. 376-383Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: a propensity score matching analysis옥경삼, 정정화, 정숙향, 장은선, 이종호, 김기현, 김진욱pp. 384-391
원문 보기